Under the agreement, Evonik will distribute InVitria’s blood-free rHSA portfolio to its biopharma customers
This marks Lupin’s first commercial product leveraging PrecisionSphere, a proprietary long-acting injectable (LAI) technology
Acquisition brings highly differentiated clinical-stage obesity candidates with potential to reshape the treatment landscape
The pharma giant's 11% rise in total revenue to $43.2 billion highlights consistent execution of its growth strategy
It will produce a comprehensive range of dosage forms including tablets, hard gelatin capsules, liquids, injectables, topicals, and beta-lactam products
Acquisition expands Novo Nordisk’s leadership in obesity-related comorbidities and metabolic diseases
Lupin's partnership program is designed to foster collaborations with companies looking to extend their product lifecycles
It represents a 30% increase in the company’s production capacity and introduces a segment dedicated to highly potent active ingredients
Subscribe To Our Newsletter & Stay Updated
